What Is a PSUR?
A Periodic Safety Update Report (PSUR) is the EU periodic pharmacovigilance report used to evaluate whether new and cumulative information changes the benefit-risk balance of an authorised medicinal product. It is not simply a count of adverse reactions reported during a fixed interval. A modern PSUR integrates safety, exposure, signals, important risks, benefit information and regulatory developments into a cumulative scientific assessment.
- What Is a PSUR?
- Purpose and Regulatory Framework
- Why PSURs Exist
- PSUR and PBRER: Relationship Rather Than Competition
- Reporting Frequency and the EURD List
- Data Lock Point
- What Information a PSUR Integrates
- Exposure as Context
- Signal Evaluation Within the PSUR
- Risk Evaluation
- Benefit Evaluation
- Integrated Benefit-Risk Analysis
- PSUSA: EU Single Assessment
- Roles and Governance
- Relationship With the RMP
- Relationship With Product Information
- Practical Implementation
- Potential Failure Modes
- Inspection and Regulatory Considerations
- Relationship With Other QPPV.com Articles
- Practical PSUR Review Checklist
- Key Takeaways
- References
- Regulatory Note
Purpose and Regulatory Framework
PSUR requirements arise from EU pharmaceutical legislation, including Directive 2001/83/EC, Regulation (EC) No 726/2004 and Commission Implementing Regulation (EU) No 520/2012. The detailed EU framework is described in GVP Module VII — Periodic safety update report (Rev. 1).
The format and content of the EU PSUR reflect the ICH E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER) model. EMA's current procedural page confirms that PSUR format and content are legally required under Implementing Regulation 520/2012 and further described in GVP Module VII.
Why PSURs Exist
Knowledge about a medicine continues to evolve after authorisation. A PSUR creates a structured point at which the MAH and regulators can reassess the cumulative evidence rather than react only to individual cases or isolated signals.
The report asks several connected questions:
- What new safety information emerged during the interval?
- What has changed cumulatively since the previous assessment?
- Have important signals been opened, closed or re-characterised?
- Has exposure changed materially?
- Have important identified or potential risks changed?
- Has new benefit information altered the clinical value of treatment?
- Do existing risk-minimisation measures remain appropriate?
- Does the overall benefit-risk balance remain favourable?
PSUR and PBRER: Relationship Rather Than Competition
The terms are related but not interchangeable in every regulatory context.
PBRER is the ICH scientific reporting standard. PSUR is the EU regulatory report. In the EU, the PSUR uses the PBRER-style integrated benefit-risk structure together with EU-specific procedural requirements such as EURD scheduling, PSUSA and submission through the applicable EU system.
For practical writing, the scientific architecture is essentially the PBRER model. For compliance, the author must also follow the EU PSUR procedure.
Reporting Frequency and the EURD List
The European Union reference dates (EURD) list establishes harmonised data lock points and submission frequencies for many active substances and combinations. Where an entry applies, the MAH should follow the frequency and data lock point specified there unless another applicable regulatory requirement modifies the obligation.
Not every authorised medicinal product follows the same periodicity. Some products may be exempt from routine PSUR submission, while competent authorities may request a PSUR when necessary.
The reporting schedule should therefore be derived from the current regulatory status and EURD list, not from a generic annual or six-monthly company calendar.
Data Lock Point
The data lock point (DLP) is the date up to which data are included in the reporting interval. It provides the temporal boundary for the analyses and cumulative updates within the report.
A DLP is not an internal date chosen freely for convenience when an applicable regulatory schedule already defines it. The PSUR process should ensure that data extraction, literature review, signal status, exposure information and other report inputs are aligned to the applicable DLP.
Late-breaking information arising after the DLP may still require consideration where it materially affects the conclusions. The report structure contains a dedicated place for such information rather than requiring the DLP itself to be changed retrospectively.
What Information a PSUR Integrates
The PSUR draws together evidence from across the pharmacovigilance and clinical system. Depending on the product and reporting interval, this may include:
- worldwide marketing-authorisation status and important regulatory actions;
- changes to reference safety information;
- cumulative and interval exposure;
- summary tabulations of adverse reactions and relevant clinical-trial data;
- findings from clinical, observational and non-interventional studies;
- scientific literature;
- non-clinical information where relevant;
- lack-of-efficacy information where it has safety or benefit-risk significance;
- new, ongoing and closed signals;
- evaluations of important identified and potential risks;
- effectiveness of risk minimisation where applicable;
- important benefit information; and
- the integrated benefit-risk analysis.
The value of the report lies in the relationship between these sections. A signal mentioned in the overview should be consistent with the signal-management record, reflected in risk evaluation where relevant, and carried into the benefit-risk conclusion if it is clinically important.
Exposure as Context
Adverse-event counts cannot be interpreted meaningfully without understanding how many patients were exposed, for how long and in what populations.
Exposure estimates may derive from sales, prescription, dispensing, claims, registry or study data. The method should be appropriate to the product and transparent about assumptions and limitations.
For example, converting packs sold into estimated patients requires assumptions about dose, treatment duration, adherence and stock movement. Such estimates can be useful, but their uncertainty should be acknowledged rather than presented as exact patient counts.
The purpose of exposure data is to create clinically interpretable context, not to manufacture a denominator that spontaneous reporting cannot reliably support for incidence estimation.
Signal Evaluation Within the PSUR
The PSUR is not a substitute for the continuous signal-management process. Signals should already be managed through the applicable signal procedures.
The PSUR provides a periodic integrated view of:
- signals newly identified during the interval;
- signals under evaluation;
- signals closed during the interval; and
- conclusions that change the understanding of known or potential risks.
A signal should not first become visible simply because the PSUR author discovers it while drafting the report. Conversely, the PSUR should not repeat entire signal dossiers. It should present the evaluation necessary to support the cumulative benefit-risk assessment.
Risk Evaluation
The signal and risk sections should distinguish between:
- information that suggests a possible risk;
- an important potential risk;
- an important identified risk;
- known adverse reactions that are not important safety concerns; and
- uncertainty or missing information relevant to risk management.
The report should explain how new evidence changes—or does not change—the understanding of these risks.
This is where simple tabulation becomes scientific evaluation. The author should consider severity, frequency, preventability, affected populations, uncertainty, dose or exposure relationships, alternative explanations and the effectiveness of current risk minimisation.
Benefit Evaluation
A PSUR is a benefit-risk report. Benefit information therefore matters when new evidence changes the understanding of efficacy or effectiveness relevant to the authorised indication.
The benefit section should not reproduce the original efficacy dossier. It should focus on developments such as:
- new comparative efficacy results;
- effectiveness in routine practice;
- changes in therapeutic alternatives;
- clinically important evidence in subgroups; or
- important lack-of-efficacy information.
Where benefit remains unchanged, the discussion can be proportionate.
Integrated Benefit-Risk Analysis
The integrated analysis asks whether the balance between benefits and risks remains favourable for the authorised use.
A strong analysis does more than state that benefits outweigh risks. It explains:
- which benefits remain clinically important;
- which risks and uncertainties matter most;
- what new evidence has changed since the previous evaluation;
- whether particular populations have a different balance;
- whether risk minimisation changes the practical impact of risk; and
- why the resulting overall conclusion is justified.
The final action should follow from this reasoning.
PSUSA: EU Single Assessment
When PSURs for the same active substance or combination are submitted in accordance with the EURD list, they may be assessed through the PSUR single assessment (PSUSA) procedure. This allows the EU network to evaluate the periodic benefit-risk evidence across relevant marketing authorisations in a harmonised procedure.
The outcome may lead to maintenance of the current authorisation, product-information changes, additional pharmacovigilance or risk-minimisation actions, or other regulatory measures as appropriate.
PSUSA should therefore be understood as a regulatory assessment procedure, not merely a document-submission mechanism.
Roles and Governance
PSUR preparation is usually multidisciplinary. Pharmacovigilance, safety physicians, epidemiology, regulatory affairs, clinical functions and data owners may all contribute depending on the product and evidence.
The QPPV is responsible for the establishment and maintenance of the pharmacovigilance system and should ensure that the system enables compliance with PSUR production and submission requirements. This does not create a universal requirement for the QPPV to personally author or sign every PSUR. Internal approval models may vary provided regulatory responsibilities and scientific accountability remain clear.
A robust governance process should ensure that:
- the applicable reporting schedule is known;
- source data and signal status are reconciled;
- important safety conclusions are medically reviewed;
- conflicts between the PSUR, RMP, product information and signal records are resolved;
- proposed actions have clear regulatory ownership; and
- final submission and authority follow-up are tracked.
Relationship With the RMP
The PSUR and RMP answer related but different questions.
The RMP is prospective: what are the important safety concerns, what is still unknown, and what pharmacovigilance or risk-minimisation activities are needed?
The PSUR is periodic and evaluative: what has changed in the evidence, and does that change the cumulative benefit-risk balance or the risk-management strategy?
A significant PSUR conclusion may therefore lead to an RMP update, but the documents should not be forced to contain identical material. Their conclusions should be scientifically consistent.
Relationship With Product Information
When a PSUR identifies evidence that changes the authorised safety information, the resulting regulatory procedure may lead to updates to the SmPC, package leaflet or other product information.
The PSUR should distinguish between:
- changes already implemented during the reporting interval;
- changes proposed by the MAH;
- changes recommended or required by a competent authority; and
- issues still under evaluation.
This distinction prevents a proposal from being presented as an agreed regulatory outcome.
Practical Implementation
A reliable PSUR process can be organised around the following sequence:
- confirm whether a PSUR is required and identify the applicable EURD/DLP and submission schedule;
- define the reporting population, products and reference information;
- collect interval and cumulative evidence from controlled sources;
- reconcile exposure, cases, studies, literature and signal status;
- evaluate new signals and changes to known risks;
- assess important new benefit information;
- integrate benefits, risks and uncertainty into one conclusion;
- identify any resulting RMP, product-information, study or risk-minimisation actions;
- complete scientific and regulatory quality review; and
- submit through the applicable procedure and track follow-up.
This is recommended operational practice rather than a universal company workflow prescribed by EMA.
Potential Failure Modes
The following are illustrative failure modes, not reported inspection findings.
| Failure mode | Why it matters |
|---|---|
| company calendar is used instead of current EURD requirements | submission frequency or DLP may be wrong |
| DLP is treated as a flexible internal planning date | report boundaries no longer match the regulatory cycle |
| exposure estimate is presented without assumptions | apparent precision may be misleading |
| PSUR discovers signals not visible in signal management | continuous surveillance and periodic reporting are disconnected |
| signal conclusions differ between PSUR and signal records | scientific governance is inconsistent |
| risk section lists data without evaluating what changed | report becomes descriptive rather than evaluative |
| benefit section copies historical efficacy text | current benefit-risk assessment is weakened |
| integrated analysis simply states “benefits outweigh risks” | reasoning cannot be followed |
| QPPV signature is treated as the sole evidence of governance | system control is reduced to an approval formality |
| proposed label change is written as if already agreed | regulatory status is misstated |
Inspection and Regulatory Considerations
An inspector or assessor may ask:
- How is the organisation determining which PSURs are due?
- How is the applicable DLP controlled?
- Can key figures and exposure estimates be traced to source data?
- Does the signal inventory reconcile with the signal-management system?
- Are important risks consistent with the RMP and product information?
- How were contradictory data handled?
- Why was the benefit-risk conclusion reached?
- Were actions arising from the previous PSUR or PSUSA implemented?
- How does the QPPV obtain visibility of important conclusions and compliance risks?
The decisive evidence is scientific and procedural consistency across the system, not the existence of a special PSUR inspection pack.
Relationship With Other QPPV.com Articles
This article provides the foundational explanation of the EU PSUR.
For the wider PBRER/PSUR regulatory framework, see [[pbrer-guide]]. For the logic connecting individual sections, see [[understanding-the-structure-of-a-pbrer]]. For detailed authoring practice, see [[how-to-write-a-pbrer]] and the dedicated section-writing articles.
Practical PSUR Review Checklist
- Is the current regulatory requirement and EURD schedule confirmed?
- Is the DLP correct for the applicable procedure?
- Are reference safety information and product scope clear?
- Are exposure methods and limitations transparent?
- Do case and study data reconcile with controlled sources?
- Does the signal overview match the signal-management system?
- Are new and cumulative risk conclusions distinguished?
- Is risk-minimisation effectiveness considered where applicable?
- Does the benefit evaluation focus on information relevant to the current balance?
- Does the integrated analysis explain rather than merely assert the conclusion?
- Are proposed actions distinguished from agreed regulatory actions?
- Are PSUR, RMP, product information and signal conclusions consistent?
Key Takeaways
A PSUR is the EU periodic benefit-risk evaluation report for authorised medicines; it is not simply an interval adverse-event summary.
Its scientific structure is aligned with ICH E2C(R2) PBRER principles, while its EU regulatory operation depends on GVP Module VII, the EURD list and applicable PSUSA or other procedural requirements.
The DLP defines the reporting boundary and should follow the applicable regulatory schedule rather than an arbitrary internal calendar.
Signal evaluation, risk evaluation, benefit evaluation and integrated benefit-risk analysis should form one connected argument.
The QPPV requires effective oversight of the pharmacovigilance system supporting PSUR compliance, but a universal QPPV authorship or signature requirement should not be invented.
References
- European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VII — Periodic safety update report (Rev. 1). EMA/816292/2011 Rev. 1.
- European Medicines Agency. Periodic safety update reports (PSURs). Current procedural guidance, including EURD and PSUSA information.
- European Medicines Agency. GVP Module VII — Explanatory note. Rev. 4, updated 22 May 2026.
- European Medicines Agency. Questions and answers on periodic safety update report single-assessment (PSUSA): Guidance document for assessors. Rev. 1, updated 22 May 2026.
- European Medicines Agency. Post-authorisation procedural advice for users of the centralised procedure. EMEA-H-19984/03 Rev. 118, updated 13 July 2026.
- International Council for Harmonisation. ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER). Step 4, 15 November 2012.
- European Union. Commission Implementing Regulation (EU) No 520/2012, as amended.
- European Union. Directive 2001/83/EC, as amended.
- European Union. Regulation (EC) No 726/2004, as amended.
Regulatory Note
This article describes the EU PSUR framework as of 8 September 2026. GVP Module VII Rev. 1 remains the published module. EMA's PSUR explanatory note and PSUSA assessor Q&A were updated on 22 May 2026, and centralised post-authorisation procedural advice is Rev. 118, updated 13 July 2026. Submission frequency, DLP and procedural requirements should always be checked against the current EURD list and applicable EMA/NCA guidance.